# Study of ST-1898 in Advanced Renal Cell Carcinoma

Source: https://onco.cc/trials/nct06127238/  
OnCo record `nct06127238` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of ST-1898 tablets in renal cell carcinoma, run by Beijing Scitech-Mq Pharmaceuticals Limited, active and no longer recruiting.

## Summary

Study of ST-1898 in Advanced Renal Cell Carcinoma is a phase 1/2 interventional study registered as NCT06127238 by Beijing Scitech-Mq Pharmaceuticals Limited, with 90 participants enrolled, started 2023-02-07 and due to reach its primary completion in 2025-12. Interventions recorded: ST-1898 tablets.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06127238
- Phase: 1/2
- Setting: A Phase Ib/II Study of ST-1898 to Evaluate the Efficacy and Safety in Patients With Renal Cell Carcinoma (RCC)
- Sponsor: Beijing Scitech-Mq Pharmaceuticals Limited
- Enrolled: 90

## Sources

- ClinicalTrials.gov NCT06127238: https://clinicaltrials.gov/study/NCT06127238

## Connected records

- cancers: [Renal cell carcinoma](https://onco.cc/cancers/rcc/)
- companies: [Beijing Scitech-Mq Pharmaceuticals](https://onco.cc/companies/beijing-scitech-mq-pharmaceuticals/)

---
JSON: https://onco.cc/api/v1/entities/nct06127238.json